XLO — Xilio Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $35.81m
- $1.83m
- 12
- 22
- 45
- 16
Annual cashflow statement for Xilio Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.3 | -55.2 | -75.8 | -88.2 | -76.4 |
| Depreciation | |||||
| Non-Cash Items | -1.57 | 1.46 | 5.35 | 8.65 | 7.54 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.797 | 16.6 | -11.8 | 2 | -1.66 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -17.8 | -36.1 | -80.8 | -75.7 | -68.6 |
| Capital Expenditures | -0.715 | -2.19 | -1.1 | -1.87 | -0.486 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.715 | -2.19 | -1.1 | -1.87 | -0.486 |
| Financing Cash Flow Items | — | — | -0.75 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 60 | 10 | 261 | -0.069 | -6.55 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 41.5 | -28.3 | 179 | -77.7 | -75.7 |